LivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024. In the quarter to June 2026, revenue grew 10.8%, EPS grew 296.0%, free cash flow fell 26.7% and total debt fell 31.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow LIVN
LivaNova PLC (LIVN) EV/Sales
As of 16 October 2026, LivaNova PLC (LIVN) trades at a EV/Sales of 2.7×. Over the past ten years it has ranged from 1.4× (April 2025) to 6.1× (September 2018); the current reading is higher than 37% of that period. That is above the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.2× | 15.78% |
| FY2024 | 1.9× | (18.70%) |
| FY2023 | 2.4× | (18.63%) |
| FY2022 | 2.9× | (32.34%) |
| FY2021 | 4.3× | 11.13% |
| FY2020 | 3.9× | 7.07% |
| FY2019 | 3.6× | (12.09%) |
| FY2018 | 4.1× | 6.79% |
| FY2017 | 3.9× | 61.91% |
| FY2016 | 2.4× | (56.43%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.9× | 29.84% |
| Mar 2026 | 2.2× | 0.79% |
| Dec 2025 | 2.2× | 13.60% |
| Sep 2025 | 2.0× | 12.12% |
| 44 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LIVN LivaNova PLC | 2.7× |
| BRKR Bruker Corporation compare | 2.9× |
| ITGR Integer Holdings Corporation compare | 3.0× |
| NEOG Neogen Corporation compare | 3.6× |
| UFPT UFP Technologies, Inc. compare | 3.8× |
| TMDX TransMedics Group, Inc. compare | 4.2× |
| IRTC iRhythm Holdings, Inc. compare | 4.4× |
| HAE Haemonetics Corporation compare | 4.7× |
| BFLY Butterfly Network, Inc. compare | 16.3× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)